Last reviewed · How we verify
Cardioplegia Solution
Cardioplegia solution induces rapid cardiac arrest and provides myocardial protection during cardiac surgery by delivering a balanced electrolyte and metabolic substrate solution to the heart.
Cardioplegia solution induces rapid cardiac arrest and provides myocardial protection during cardiac surgery by delivering a balanced electrolyte and metabolic substrate solution to the heart. Used for Myocardial protection during cardiac surgery requiring cardiopulmonary bypass.
At a glance
| Generic name | Cardioplegia Solution |
|---|---|
| Also known as | Cardioplexol™ |
| Sponsor | Washington University School of Medicine |
| Drug class | Cardioplegia solution |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
The solution works by creating a controlled, reversible cessation of cardiac contractions through potassium-induced depolarization, reducing myocardial oxygen demand during the ischemic period of surgery. It simultaneously provides essential substrates (glucose, amino acids) and buffering agents to preserve cellular function and prevent ischemic injury, allowing the surgeon to operate on a still, bloodless field while maintaining myocardial viability for post-operative recovery.
Approved indications
- Myocardial protection during cardiac surgery requiring cardiopulmonary bypass
Common side effects
- Hyperkalemia
- Myocardial edema
- Reperfusion injury
- Arrhythmias post-operatively
Key clinical trials
- Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegia
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Effect of the Addition of Adenosine on Myocardial Protection During Cardiopulmonary Bypass (PHASE4)
- Cardioplegic Protection of the Heart (PHASE4)
- Study of Cardioplegia in Cardiac Surgery Due to Congenital Heart Malformation in Children (PHASE2)
- Impact of Different Cardioplegia Solutions on Indicators of Myocardial Injury During Coronary Surgery (NA)
- Landiolol in Mitral Valve Surgery (PHASE4)
- Ringer Acetate Based Modified Del Nido Cardioplegia Solution Versus HTK Solution Cardioplegia Solution in Cardiac Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cardioplegia Solution CI brief — competitive landscape report
- Cardioplegia Solution updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI